Irbesartan + Hidroclorotiazida Azevedos (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and reducing aldosterone‑mediated sodium retention, which leads to vessel relaxation. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. Together, these mechanisms produce an additive reduction in blood pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood‑pressure goals, renal function, and other individual factors. Healthcare professionals adjust the dosage to achieve optimal control while monitoring safety, and patients should follow the specific instructions provided by their prescriber.

The product is classified as Pregnancy Category D, indicating evidence of risk to the fetus and that it should be avoided unless the potential benefit justifies the risk. It is also not recommended for breastfeeding mothers because it may pass into breast milk and affect the infant. Consultation with a healthcare provider is essential before use in these situations.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Irbesartan/Hydrochlorothiazide offers a dual mechanism—angiotensin II blockade plus thiazide‑induced diuresis—providing stronger blood‑pressure reduction than either component alone. Compared with single‑agent ACE inhibitors or ARBs, the combination can achieve target pressures with fewer tablets, but it may carry a higher risk of electrolyte disturbances and requires monitoring of potassium and renal function.

The tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral solid dosage form.

The medication is taken orally, usually once daily, with a full glass of water. It may be taken with or without food, but patients should follow the specific timing advised by their prescriber to maintain consistent blood‑pressure control.

Serious adverse events include severe hypotension, significant electrolyte imbalances such as hyperkalemia, and rare but potentially life‑threatening angioedema. Patients should seek immediate medical attention if they experience swelling of the face, lips, tongue, or difficulty breathing, as well as symptoms of very low blood pressure like fainting or dizziness.

The combination is contraindicated in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, anuria, or those who are pregnant. Clinicians must assess each patient’s medical history before initiating therapy.